120 related articles for article (PubMed ID: 36074152)
1. Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Dong P; Zhang X; Peng Y; Zhang Y; Liu R; Li Y; Pan Q; Wei W; Guo S; Zhang Z; Han H; Zhou F; Liu Y; He L
Clin Cancer Res; 2022 Nov; 28(21):4807-4819. PubMed ID: 36074152
[TBL] [Abstract][Full Text] [Related]
2. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G
Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114
[TBL] [Abstract][Full Text] [Related]
3. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
4. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas.
Yoo A; Tang C; Zucker M; Fitzgerald K; DiNatale RG; Rappold PM; Weiss K; Freeman B; Lee CH; Schultz N; Motzer R; Russo P; Coleman J; Reuter VE; Chen YB; Carlo MI; Gill AJ; Kotecha RR; Ari Hakimi A; Reznik E
Eur Urol Focus; 2022 Sep; 8(5):1278-1288. PubMed ID: 35288096
[TBL] [Abstract][Full Text] [Related]
5. Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases.
Pivovarcikova K; Martinek P; Grossmann P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Pane Foix M; Condom Mundo E; Berney D; Gill A; Rychly B; Michalova K; Rogala J; Pitra T; Micsik T; Polivka J; Hora M; Tanas Isikci O; Skalova S; Mareckova J; Michal M; Hes O
Ann Diagn Pathol; 2019 Apr; 39():63-68. PubMed ID: 30785029
[TBL] [Abstract][Full Text] [Related]
6. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.
Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O
Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557
[TBL] [Abstract][Full Text] [Related]
7. Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues.
Yoo SH; Yun J; Keam B; Hong SP; Ock CY; Koh J; Kim S; Jeon YK; Jung KC; Kim M; Kim TM; Kim DW; Kim JI; Heo DS
Cancer Immunol Immunother; 2021 Jun; 70(6):1755-1769. PubMed ID: 33389015
[TBL] [Abstract][Full Text] [Related]
8. Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.
Liang J; Sun G; Pan X; Zhang M; Shen P; Zhu S; Zhao J; Zheng L; Zhao J; Chen Y; Yin X; Chen J; Hu X; Zeng Y; Chen J; Wang Y; Liu Z; Yao J; Su M; Huang R; Liao B; Wei Q; Li X; Zhou Q; Liu J; Shen Y; Liu Z; Chen N; Zeng H; Zhang X
Genome Med; 2023 May; 15(1):31. PubMed ID: 37131267
[TBL] [Abstract][Full Text] [Related]
9. Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression.
Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
Cancer Res Treat; 2023 Oct; 55(4):1321-1336. PubMed ID: 37024096
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Gleeson JP; Nikolovski I; Dinatale R; Zucker M; Knezevic A; Patil S; Ged Y; Kotecha RR; Shapnik N; Murray S; Russo P; Coleman J; Lee CH; Stadler ZK; Hakimi AA; Feldman DR; Motzer RJ; Reznik E; Voss MH; Chen YB; Carlo MI
Clin Cancer Res; 2021 May; 27(10):2910-2919. PubMed ID: 33658299
[TBL] [Abstract][Full Text] [Related]
11. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.
Golkaram M; Kuo F; Gupta S; Carlo MI; Salmans ML; Vijayaraghavan R; Tang C; Makarov V; Rappold P; Blum KA; Zhao C; Mehio R; Zhang S; Godsey J; Pawlowski T; DiNatale RG; Morris LGT; Durack J; Russo P; Kotecha RR; Coleman J; Chen YB; Reuter VE; Motzer RJ; Voss MH; Liu L; Reznik E; Chan TA; Hakimi AA
Genome Med; 2022 Dec; 14(1):143. PubMed ID: 36536472
[TBL] [Abstract][Full Text] [Related]
12. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
Front Immunol; 2021; 12():657951. PubMed ID: 34531849
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
Davidson G; Helleux A; Vano YA; Lindner V; Fattori A; Cerciat M; Elaidi RT; Verkarre V; Sun CM; Chevreau C; Bennamoun M; Lang H; Tricard T; Fridman WH; Sautes-Fridman C; Su X; Plassard D; Keime C; Thibault-Carpentier C; Barthelemy P; Oudard SM; Davidson I; Malouf GG
Cancer Res; 2023 Sep; 83(17):2952-2969. PubMed ID: 37335139
[TBL] [Abstract][Full Text] [Related]
14. Diffuse Carbonic Anhydrase 9 and GATA3 Expression in Fumarate Hydratase Deficient Renal Cell Carcinoma - A Case Report and Immunoprofile Review.
Pacheco RR; Pacheco R; Cooley C; Kaufman R; Akgul M
Int J Surg Pathol; 2024 Feb; 32(1):145-149. PubMed ID: 37050851
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
16. Single-cell transcriptomics reveals a low CD8
Peng YL; Xiong LB; Zhou ZH; Ning K; Li Z; Wu ZS; Deng MH; Wei WS; Wang N; Zou XP; He ZS; Huang JW; Luo JH; Liu JY; Jia N; Cao Y; Han H; Guo SJ; Dong P; Yu CP; Zhou FJ; Zhang ZL
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35121646
[TBL] [Abstract][Full Text] [Related]
17. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Lu X; Vano YA; Su X; Helleux A; Lindner V; Mouawad R; Spano JP; Rouprêt M; Compérat E; Verkarre V; Sun CM; Bennamoun M; Lang H; Barthelemy P; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Cell Rep Med; 2023 Nov; 4(11):101287. PubMed ID: 37967556
[TBL] [Abstract][Full Text] [Related]
18. Multidetector CT Characteristics of Fumarate Hydratase-Deficient Renal Cell Carcinoma and Papillary Type II Renal Cell Carcinoma.
Yang L; Li XM; Hu YJ; Zhang MN; Yao J; Song B
Korean J Radiol; 2021 Dec; 22(12):1996-2005. PubMed ID: 34668351
[TBL] [Abstract][Full Text] [Related]
19. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
[TBL] [Abstract][Full Text] [Related]
20. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]